J Med Chem. 2021 Jul 8;64(13):9550-9566. doi: 10.1021/acs.jmedchem.1c00880. Epub 2021 Jun 17.
Preclinical and clinical data reveal that inflammation is strongly correlated with the pathogenesis of a number of diseases including those of cancer, Alzheimer, and diabetes. The inflammatory cascade involves a multitude of cytokines ending ultimately with the activation of COX-2/LOX for the production of prostaglandins and leukotrienes. While the available inhibitors for these enzymes suffer from nonoptimal selectivity, in particular for COX-2, we present here the results of purposely designed tartarate derivatives that exhibit favorable selectivity and significant effectiveness against COX-2 and LOX. Integrated approaches of molecular simulation, organic synthesis, and biochemical/physical experiments identified inhibiting COX-2 and LOX with respective IC 4 and 7 nM. At a dose of 5 mg kg to Swiss albino mice, reversed algesia by 65% and inflammation by 33% in 2-3 h. We find good agreement between experiments and simulations and use the simulations to rationalize our observations.
临床前和临床数据表明,炎症与许多疾病的发病机制密切相关,包括癌症、阿尔茨海默病和糖尿病。炎症级联反应涉及多种细胞因子,最终导致 COX-2/LOX 的激活,从而产生前列腺素和白三烯。虽然这些酶的现有抑制剂存在非最佳选择性,特别是对 COX-2,我们在这里介绍了经过专门设计的酒石酸盐衍生物的结果,这些衍生物对 COX-2 和 LOX 表现出有利的选择性和显著的有效性。分子模拟、有机合成和生化/物理实验的综合方法确定了抑制 COX-2 和 LOX 的 IC 4 和 7 nM。在 5mgkg 的剂量下,瑞士白化病小鼠的镇痛作用在 2-3 小时内逆转了 65%,炎症反应逆转了 33%。我们发现实验和模拟之间有很好的一致性,并利用模拟来合理化我们的观察结果。